The University of Kentucky (UK) has announced a research collaboration with Atomwise to explore potential COVID-19 therapies. An associate professor in UK’s college of medicine was granted the project from Atomwise’s Artificial Intelligence (AI) Molecular Screen award program, which seeks to democratize access to AI for drug discovery and enable researchers to accelerate the translation of their research into novel […]
The University of Kentucky announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies. The project awarded to Dr. Konstantin V. Korotkov is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) awards program, which seeks to democratize access to AI for drug […]
University of Connecticut professor of molecular and cell biology James Cole is working on identifying new therapeutics for COVID-19. Through a collaboration with Atomwise, Cole is one of the 15 researchers looking at different coronavirus protein targets for COVID-19 treatment.
The University of Kentucky announced a research collaboration with Atomwise, an industry leader in using artificial intelligence (AI) for small molecule discovery, to explore potential COVID-19 therapies.
AI-based drug discovery specialist Atomwise has revealed details of 15 research collaborations seeking… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
There are presently 15 research collaborations underway to enable academic researchers to discover novel therapies for the COVID-19 pandemic and those in the future using advanced artificial intelligence (AI) technology developed by Atomwise Inc. (San Francisco, CA, USA).